0001062993-17-005006.txt : 201711150001062993-17-005006.hdr.sgml : 2017111520171115170009ACCESSION NUMBER:0001062993-17-005006CONFORMED SUBMISSION TYPE:8-KPUBLIC DOCUMENT COUNT:29CONFORMED PERIOD OF REPORT:20171115ITEM INFORMATION:Regulation FD DisclosureITEM INFORMATION:Financial Statements and ExhibitsFILED AS OF DATE:20171115DATE AS OF CHANGE:20171115

FILER:

COMPANY DATA:COMPANY CONFORMED NAME:BIOSPECIFICS TECHNOLOGIES CORPCENTRAL INDEX KEY:0000875622STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:113054851STATE OF INCORPORATION:DEFISCAL YEAR END:1231

FILING VALUES:FORM TYPE:8-KSEC ACT:1934 ActSEC FILE NUMBER:001-34236FILM NUMBER:171205782

BUSINESS ADDRESS:STREET 1:35 WILBUR STCITY:LYNBROOKSTATE:NYZIP:11563BUSINESS PHONE:5165937000

MAIL ADDRESS:STREET 1:35 WILBUR STREETCITY:LYNBROOKSTATE:NYZIP:11563

8-K1form8k.htmFORM 8-K

Biospecifics Technologies Corp.: Form 8-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities ExchangeAct of 1934

Date of Report (Date of earliest event reported): November14, 2017

BIOSPECIFICS TECHNOLOGIESCORP.
(Exact name of registrant as specified in itscharter)

Delaware 001-34236 11-3054851 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)
35 Wilbur Street 11563 Lynbrook, NY (Address of principal executive offices) (Zip Code)

Registrants telephone number, including area code:516.593.7000

N/A
(Former name or former address, ifchanged since last report)

Check the appropriate box below if the Form 8-K filing isintended to simultaneously satisfy the filing obligation of the registrant underany of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under theSecurities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under theExchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) Indicate by check markwhether the registrant is an emerging growth company as defined in Rule 405 ofthe Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if theregistrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act. [ ]

2

Introductory Comment

Throughout this Current Report on Form 8-K, the terms we,us, our and Company refer to BioSpecifics Technologies Corp.

Item 7.01 Regulation FD Disclosure

Officers and representatives of the Company will present tovarious investors and stockholders beginning November 14, 2017 using thepresentation materials furnished as Exhibit 99.1 hereto and which areincorporated herein by reference.

The information in this report (including Exhibit 99.1) shallnot be deemed to be filed for purposes of Section 18 of the SecuritiesExchange Act of 1934, as amended (the Exchange Act), or otherwise subject tothe liability of that section, and shall not be incorporated by reference intoany registration statement or other document filed under the Securities Act of1933, as amended, or the Exchange Act, except as shall be expressly set forth byspecific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit Description No. 99.1 Presentation materials to be used by officers and other representatives of the Company

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned hereunto duly authorized.

Dated: November 14, 2017

BioSpecifics Technologies Corp. By: /s/ Thomas L. Wegman Name: Thomas L. Wegman Title: President

4

EXHIBIT INDEX

Exhibit Description No. 99.1 Presentation materials to be used by officers and other representatives of the Company

5

EX-99.12exhibit99-1.htmEXHIBIT 99.1

Biospecifics Technologies Corp.: Exhibit 99.1 - Filed by newsfilecorp.com

GRAPHIC3exhibit99-1x1x1.jpgGRAPHIC

begin 644 exhibit99-1x1x1.jpg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